| 引用本文: | 马腾,穆丽婷,田昕彤,杨继,赵英强*.达格列净治疗心力衰竭合并2型糖尿病的系统评价及序贯分析[J].中国现代应用药学,2024,41(7):968-978. |
| MA Teng,MU Liting,TIAN Xintong,YANG Ji,ZHAO Yingqiang*.Dapagliflozin in the Treatment of Heart Failure with Diabetes Mellitus Type 2: a Systematic Review and Sequential Analysis[J].Chin J Mod Appl Pharm(中国现代应用药学),2024,41(7):968-978. |
|
| 摘要: |
| 目的 系统评价达格列净治疗心力衰竭合并2型糖尿病患者的临床疗效。方法 检索Embase、PubMed、Web of Science、Cochrane Library、维普、中国知网、万方数据库中关于达格列净治疗心力衰竭合并2型糖尿病的临床试验，时间范围从建库至2022年3月18日。通过使用RevMan5.3软件对各指标进行meta分析，使用TSA 0.9进行序贯分析。结果 最终纳入31项符合标准的随机对照研究，涉及患者2 906例。Meta分析结果显示，相比于对照组，试验组显著提高了左心室射血分数[MD=4.43，95%CI(3.35，5.50)，P<0.000 01]、总有效率[MD=4.19，95%CI(2.52，6.99)，P<0.000 01]，降低了N端脑钠肽前体[MD=–451.84，95%CI(–608.09，–295.60)，P<0.000 01]、左心室舒张末期内径[MD=–2.74，95%CI(–3.67，–1.82)，P<0.000 01]、糖化血红蛋白[MD =–0.88，95%CI(–1.19，–0.57)，P<0.000 01]、空腹血糖[MD=–1.10，95%CI(–1.45，–0.75)，P<0.000 01]、餐后2 h血糖[MD=–2.52，95%CI(–3.37，–1.66)，P<0.000 01]及不良反应发生率[MD=0.63，95%CI(0.47，0.83)，P＝0.001]。试验序贯分析表明，达格列净提高心力衰竭合并2型糖尿病患者左心室射血分数疗效确切，排除假阳性可能。结论 达格列净治疗心力衰竭合并2型糖尿病患者具有良好疗效，且安全性好，但日后仍有待于纳入更多高质量随机对照研究进一步论证。 |
| 关键词: 达格列净 心力衰竭 2型糖尿病 序贯分析 |
| DOI：10.13748/j.cnki.issn1007-7693.20221358 |
| 分类号:R969.3 |
| 基金项目:天津卫生健康委员会中医中西医结合科研课题(2021112) |
|
| Dapagliflozin in the Treatment of Heart Failure with Diabetes Mellitus Type 2: a Systematic Review and Sequential Analysis |
|
MA Teng1, MU Liting2, TIAN Xintong1, YANG Ji1, ZHAO Yingqiang*2
|
|
1.Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China;2.The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China
|
| Abstract: |
| OBJECTIVE To systematically evaluate the clinical efficacy of dapagliflozin in the treatment of heart failure with diabetes mellitus type 2. METHODS The clinical trials of dapagliflozin in the treatment of heart failure with diabetes mellitus type 2 were searched in Embase, PubMed, Web of Science, Cochrane Library, VIP, CNKI and Wanfang databases from the establishment of the database to March 18, 2022. The RevMan 5.3 software was used for meta-analysis, and the TSA 0.9 software was used for sequential analysis. RESULTS The 31 RCT studies meeting the criteria were finally included, involving 2 906 patients. Meta-analysis showed that compared with the control group, the experimental group significantly improved LVEF[MD=4.43, 95% CI(3.35, 5.50), P<0.000 01], total effective rate[MD=4.19, 95%CI(2.52, 6.99), P<0.000 01], and reduced NT-proBNP[MD=–451.84, 95%CI(–608.09, –295.60), P<0.000 01], LVEDD[MD=–2.74, 95%CI(–3.67, –1.82), P<0.000 01, Hb1ac[MD=–0.88, 95%CI(–1.19, –0.57), P<0.000 01], FPG[MD=–1.10, 95%CI(–1.45, –0.75), P<0.000 01], 2hPG[MD=–2.52, 95%CI(–3.37, –1.66), P<0.000 01] and the incidence of adverse reactions[MD=0.63, 95%CI(0.47, 0.83), P=0.001]. Sequential analysis showed that the effect of dapagliflozin on LVEF in patients with heart failure with type 2 diabetes was accurate, and the possibility of excluding false positive was possible. CONCLUSION The treatment of heart failure with diabetes mellitus type 2 with good efficacy and safety is achieved by dapagliflozin, but it still needs to be included in more high-quality RCT studies for further demonstration. |
| Key words: dapagliflozin heart failure type 2 diabetes mellitus sequential analysis |
